Suzetrigine, sold under the brand name Journavx, is an oral medication used for moderate to severe acute pain management in adults. [1][2] It is a small-molecule non- opioid analgesic that works as a …

Jan 30, 2025 · Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in …

Feb 3, 2025 · Journavx (suzetrigine) is a new non-opioid pain-relieving tablet used to treat short-term (acute) moderate to severe pain. Journavx is a sodium channel blocker that relieves pain by blocking …

JOURNAVX is a prescription medicine used to treat adults with moderate-to-severe short-term (acute) pain. It is not known if JOURNAVX is safe and effective in children. Do not take JOURNAVX if you …

Nov 1, 2025 · Description Suzetrigine is used to treat moderate to severe short-term pain. This medicine is available only with your doctor's prescription. This product is available in the following dosage …

Suzetrigine is the first novel mechanism of action analgesic approved in decades. In acute, post-operative pain it has a modest reduction in pain, with a small effect size that is numerically better …

Why is this medication prescribed? Suzetrigine is used as a short-term treatment to relieve moderate to severe pain. Suzetrigine is in a class of medications called sodium channel blockers. It works by …

Suzetrigine (VX-548) is a potent and selective inhibitor of Na V 1.8, which has demonstrated clinical efficacy and safety in multiple acute pain studies.

May 1, 2025 · Suzetrigine, a selective sodium-channel blocker that inhibits nociceptive pain signaling in peripheral nerves, was approved by the FDA in January 2025 “for the treatment of moderate to …

Jan 31, 2025 · Suzetrigine is a non-opioid medication that treats moderate-to-severe pain in adults. It’s meant for acute (short-term) use, not chronic use. It’s a 50 mg oral tablet that you can take twice …